CN1720924A - Application of montmorillonite in pharmacy - Google Patents
Application of montmorillonite in pharmacy Download PDFInfo
- Publication number
- CN1720924A CN1720924A CNA2005100827570A CN200510082757A CN1720924A CN 1720924 A CN1720924 A CN 1720924A CN A2005100827570 A CNA2005100827570 A CN A2005100827570A CN 200510082757 A CN200510082757 A CN 200510082757A CN 1720924 A CN1720924 A CN 1720924A
- Authority
- CN
- China
- Prior art keywords
- montmorillonitum
- substance
- intestinal
- digestive tracts
- montmorillonite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the novel use of montmorillonite in pharmaceutical industry, after oral administration, the substance can adsorb various endogenous and exogenous virulence factors in digestive tracts, and is discharged along with the adsorbed virulence factors through the creeping motion of the digestive tracts, thus the substance can be used as pathogen cleaning agent in digestive tracts, it also has the function of ion exchange which is not influenced by hydrogen ion concentration. The use of the substance in treating chronic kidney failure is also disclosed in the invention.
Description
Technical field the present invention relates to Montmorillonitum, is commonly called as the bentonite purposes of (available its micron order, nanoscale and micron order thereof mix with different proportionings with nanoscale), relates in particular to the purposes in pharmaceutical field.
The general living pharmacy of background technology France Bo Fu-benefit group has realized Montmorillonitum medicinal application clinically in China since 1989, it has the history of the clinical practice in 20 years abroad; This property of medicine structure of matter is the microgranule powder of the multiple structure of the octahedra aluminium oxide of natural ditetrahedron silicon oxide [Si8AL4020 (OH) 4] composition, have lamellar structure and interlayer heterogeneity CHARGE DISTRIBUTION, expand, disperse and suspend after meeting water, form trickle slit between layer and the layer, it is believed that, this medicine can be adsorbed onto various types of inside and outside source sexual assault factors in these slits in digestive tract, and the absorption back is difficult for taking place desorption and separates suction phenomenon; Be because Montmorillonitum with have very big close-burning result after water mixes
(1) (2) (3)
Existing known Montmorillonitum can the chelating digestive tract in cholic acid, cholate, toxin, gas and the endogenous toxin etc. of virus, pathogenic bacteria and generation thereof are had extremely strong fixing, inhibitory action, can make the above-mentioned former pathogenicity that loses of causing a disease; The digestion mucous membrane there is very strong covering protection ability, has reparation, improve of defense function, balance flora and the local analgesic hemostatic effect of mucosa barrier attack factor
(4)Go up report on February 10th, 2003 " daily magazine industry news ", the rich experimental result display body in pool, Japanese Fructus Pruni woods university lecturer palace has the absorption anaphylactogen outward, plays anti-allergic effects, and its absorbability specific activity charcoal is high 1 times, and this scholar has applied for patent at this point.
The Montmorillonitum avirulence is to people, animal, plant nonhazardous and corrosiveness
(5), in the treatment of infantile diarrhea as first-selected medication, its safety non-toxic, non-stimulated to human body skin, neural, respiratory system are not had influence, can be used for medical carrier
(6), side effect is that a large amount of backs of using produce just close symptom
(7)
After Montmorillonitum is oral, have the function with the multiple inside and outside borne pathogenic factor absorption in the digestive tract, it is discharged with digestive tract self wriggling together with adsorbed virulence factor; This material is as cause of disease scavenger in the digestive tract, and avirulence is not absorbed by digestive tract, do not enter blood circulation, this material adhesive property is strong, and the absorption back takes place, and it is fixed effective, promptly be difficult for the desorption desorbing, and have ion exchange to reach characteristics such as not being subject to the hydrogen ion concentration influence.
Summary of the invention the object of the present invention is to provide the new purposes of Montmorillonitum, both the new application in pharmacy.
In fact, the present invention relates to the application of Montmorillonitum in the medicine for the treatment of chronic renal failure as preparation.
In order to understand essence of the present invention better, will its new purposes in pharmaceutical field be described with Montmorillonitum (available its micron order, nanoscale and micron order thereof mix with different proportionings with nanoscale) clinical effectiveness below.Similarly, use the Montmorillonitum of above-mentioned different-grain diameter all can reach same pharmacological effect separately, the difference of the proportioning that adopts or the size of side effect when difference only is that different-grain diameter mixes to each other.
The product that adopts French Bo Fu-beneficial Pu Sheng pharmaceutical Co. Ltd is as ready-made experimental drug, and this product trade name dioctahedral smectite (Smecta) whenever comprises Montmorillonitum 3g and adjuvant glucose 749mg, saccharin sodium 7mg, vanillin 4mg.
Treatment chronic renal merit declines: main principle is that the chronic renal merit is when declining, originally the protein,split blood urea nitrogen (BUN) that should excrete via kidney, potassium ion etc. can not have been discharged by kidney, and piling up in vivo excessively becomes toxin and cause hyperpotassemia etc.Behind the oral intestinal canal adsorbent, this adsorbent spreads out in intestinal and is attached to the intestinal mucosa surface, its adsorption produces the change of intestinal mucosa surface seepage pressure reduction, making the interior toxin of intestinal mucosa, potassium ion etc. be adsorbed out both dialyses out, these are dialysed out to go forward side by side and together excrete with intestinal contents subsequently into the toxin of intestinal, potassium ion etc., reduce the concentration of this toxin, potassium ion etc. in the body, reached the intestinal dialysis effect.The representative drugs that has same purpose at present: active carbon, be used widely in clinical at home and abroad, the Montmorillonitum mechanism of action is similar with it, more since Montmorillonitum with have very big caking property after water mixes, it does not allow to be subject to the influence of hydrogen ion concentration, and the free suction phenomenon of separating of desorption can not take place after the absorption
(1) (2) (3), its ion exchange can be replaced a large amount of potassium ions, and it is better that curative effect is wanted the specific activity charcoal theoretically.The hemostatic healing efficacy of intestinal bleeding is good when having the bibliographical information Montmorillonitum that the acute kidney merit is declined; be that the digestion mucous membrane is had very strong covering protection ability; repair, improve the mucosa barrier is defendd this series function to attack factor use; but contratoxin is not adsorbed on the intestinal mucosa surface to separate out to make and describes and test, and it can not be made targetedly and summing up
(8)
The clinical research that declines to treatment chronic renal merit in the oral back of Montmorillonitum: 36 similar substantially routine chronic renal merits of the cause of disease, the state of an illness patient's randomized, double-blind that declines is divided into Montmorillonitum oral medication group 20 examples, matched group Orally active charcoal 16 examples are observed, plasma urea nitrogen (BUN) concentration level all descended CO2 combining power, CO2 CP (CO to some extent after the result showed treatment group patient and matched group patient medication
2Cap) all rise to some extent, statistical analysis does not have significant difference for two groups.
Therapeutic Method adopts: (comprise treatment protopathy, hemodialysis, correction water, electrolyte and acid base imbalance, keep nutrition of whole body etc.) on the chronic renal merit declines the conventional therapy basis, at hemodialysis oral Montmorillonitum of interval, the time be after the hemodialysis beginning in second day to hemodialysis next time the previous day; With administration in 2-3 hour after meal, one time 3 gram of being grown up, three times on the one (8 hours 1 time), the result shows that test group curative effect of medication and matched group active carbon dialyse and do not have significant difference in the curative effect in intestinal.
Nanoscale Montmorillonitum better efficacy, because the reason that nanoscale Montmorillonitum specific surface area is bigger, again because the blood urea nitrogen (BUN), the potassium ion self that enter in the intestinal are not absorbed by intestinal mucosa again, the nanoscale Montmorillonitum with blood urea nitrogen (BUN), potassium ion from the intestinal mucosa surface separate out with adsorb after the desorption desorbing curative effect is not had influence (the more little easy more desorbing of particle diameter), and 1/3rd amount nanoscale Montmorillonitums are identical with a deal micron order particle diameter Montmorillonitum curative effect, take for a long time simultaneously generation constipation symptom but than Isodose micron order particle diameter Montmorillonitum to lack many.
In clinical, observe the Calamine Lotion that makes with the preparation of 2% Montmorillonitum, being coated with to put on the skin behind the skin has tangible itching-relieving action (blood urea nitrogen had accumulation when the chronic renal merit declined under skin of lower extremity the chronic renal merit skin of lower extremity pruritus that declines, cause skin pruritus), this is that Montmorillonitum adsorbs blood urea nitrogen (BUN) by skin surface and played the percutaneous Dialysis, to one of the thinking of this phenomenon thinking just of the present invention source.Bibliographical information: Montmorillonitum is used for medical ointment, can form thin film at skin surface, to other drug is antipruritic potentiation is arranged
(9) (10), do not lost reference value.
The chronic renal merit that is used for the treatment of oral medicinal smectite declines does not have bibliographical information or corresponding data at home and abroad at present.Above-mentioned therapeutic outcome shows; Decline patient's treatment of the chronic renal merit that helps medicinal smectite.
From above result, can draw and the invention has the advantages that:
(1) the present invention has excavated new medical application to known natural mineral matter Montmorillonitum, has opened up a new application.
(2) Montmorillonitum safety non-toxic of the present invention, pharmacological action is strong, is indicating well prospect in medicine.
(3) raw material of substance of the present invention source abundant, inexpensive, do not see toxic and side effects, preparation technology is simple, it is easy to use to make peroral dosage form.
(4) medicine that is mixed with of material of the present invention has adsorption function, can be after oral with all kinds virulence factor absorption in the digestive tract, and its adhesive property of absorption back is strong, is difficult for desorbing, and it is discharged with digestive tract self wriggling together with adsorbed, fixed virulence factor; Belong to cause of disease scavenger in the digestive tract.
(5) Montmorillonitum of the present invention has adsorption and ion exchanging function, form in the body in the time of the chronic renal merit can being declined and bulk deposition blood urea nitrogen (BUN), potassium ion etc. separate out by the intestinal mucosa surface adsorption; It excretes the back with digestive tract self wriggling together with adsorbed, fixed blood urea nitrogen (BUN), potassium ion etc., has reached the intestinal dialysis effect.
(6) Montmorillonitum of the present invention can be made enteric coatel tablets, also can place in the enteric coated capsule, and location in intestinal, oral back discharges, and plays location absorption in the intestinal, saturating suction effect, improves curative effect, has reduced the drug use amount.
The several embodiment of various details, but content of the present invention is not limited to this fully.
Specific embodiment example 1
Calcining of natural mineral matter Montmorillonitum process or roasting are pulverized the back of sieving and are adopted the technological standards of France to do clinical application, and this medicine whenever comprises Montmorillonitum 3g, adjuvant glucose 749mg, saccharin sodium 7mg, vanillin 4mg.
Specific embodiment example 2
Calcining of natural mineral matter Montmorillonitum process or roasting are made into 2.31 microns powder of mean diameter after pulverizing and sieving; Its expansion capacity (ml/g) 27.0; Mix adjuvant, do powdered or powder, become bag to package spare.
Specific embodiment example 3
The natural mineral matter Montmorillonitum through calcining or roasting pulverize sieve after applied microwave technology again, the micron order Montmorillonitum is made nanometer grade powder, particle diameter is 20-300nm; Mix adjuvant and do powder or powder, become bag to package spare.
Specific embodiment example 4
After calcining of natural mineral matter Montmorillonitum process or roasting are pulverized and are sieved, micron order and nanometer grade powder carry out compatibility by the component of different-grain diameter, the employing of different-grain diameter Montmorillonitum depends on the Montmorillonitum powder and be adsorbed between the factor absorption and this equilibrated trend of desorption, and is bigger than normal for well with particle diameter as far as possible in absorption and when being fixed as main purpose.Less than normal for well with particle diameter as far as possible when separating out to main purpose from the intestinal mucosa surface, also can be according to concrete sick kind combination drug; Mix adjuvant and do powder or powder, or enteric coated capsule, become bag to package spare.
Specific embodiment example 5
Can mix into that a little laxative resists the generation of constipation with this, with laxative with do powdered or powder after Montmorillonitum mixes, become bag to package spare.
Specific embodiment example 6
Can make enteric coatel tablets in the above-mentioned routine 1-example 6, become box to package spare.
List of references
1, Ao Erfen * model (U.S.). the clay collochemistry. the 2nd edition. Beijing: agriculture publishing house, 1979.65～69
2, must the pretty man of rattan (day). clay mineralogy. Beijing: Geology Publishing House, 1981.235～258
3, Ma Yijie. bentonite resource, character and utilization thereof. agrology progress, 1994,22 (2): 21～25
4，Droy-Lefaix?MT，Drouet?Y，Schatz?B.Sodium?glycodcoxycholate?and?sprinability?ofgastrointestinal?mucous：protective?effect?of?smectite.Gastroenterology，1985，88Suppl?2：1369～1370
5, Sun Yuhua, Xing Junfen, A Li. pharmaceutic adjuvant bentonite general pharmacology is learned research. Chinese herbal medicine, 1999,30 (8): 609～610
6, Zheng Mingxin, Wang Yue, Ningde Russia. the suspending effect observation that several novel suspending agents are used for sucralfate suspesion compares. Chinese Hospitals pharmaceutical journal, 1994,14 (2): 72～73
7, Chinese Pharmacopoeia: Montmorillonitum powder description etc. (on version was equipped with in 2005)
8, Wang Yongcui. losec, dioctahedral smectite treatment uremia and upper gastrointestinal hemorrhage 30 routine clinical analysiss. China's medical science, 2002,15 (3): 336 (2) 2-8
9, Wang Houliang, Li Jianbao, yellow brave. bentonitic advanced processing technique and up-to-date purposes. Chinese Mining Industry, 1996,5 (6): 39～43
10, Xing Junfen, beam is met, Ao Bingchen. and bentonite is to the investigation of medicinal suspension suspending performance. Chinese Hospitals pharmaceutical journal, 1991,11 (2): 74～76.
Claims (1)
1. the application of Montmorillonitum in the medicine of preparation treatment chronic renal failure.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03121876 CN1267103C (en) | 2003-04-17 | 2003-04-17 | Applicaton of montmorillonite inpreparing medicine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03121876 Division CN1267103C (en) | 2003-04-17 | 2003-04-17 | Applicaton of montmorillonite inpreparing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1720924A true CN1720924A (en) | 2006-01-18 |
| CN1314406C CN1314406C (en) | 2007-05-09 |
Family
ID=34320878
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100827570A Expired - Fee Related CN1314406C (en) | 2003-04-17 | 2003-04-17 | Application of montmorillonite in pharmacy |
| CN 03121876 Expired - Fee Related CN1267103C (en) | 2003-04-17 | 2003-04-17 | Applicaton of montmorillonite inpreparing medicine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03121876 Expired - Fee Related CN1267103C (en) | 2003-04-17 | 2003-04-17 | Applicaton of montmorillonite inpreparing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN1314406C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251648A (en) * | 2013-05-15 | 2013-08-21 | 乔敏 | Iron-based montmorillonite medicine for treating hyperphosphatemia and iron-deficiency anemia and preparation method of iron-based montmorillonite medicine |
| DE102012209411A1 (en) * | 2012-06-04 | 2013-12-05 | Fim Biotech Gmbh | Mineral compound for the reduction of inorganic phosphates, in particular in the context of renal replacement therapy |
| WO2014037877A1 (en) * | 2012-09-04 | 2014-03-13 | Irccs Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino | Food product or a seasoning thereof containing bentonite or montmorillonite having activity of metabolic protein load reduction |
| ITMI20130764A1 (en) * | 2013-05-10 | 2014-11-11 | Easy & Good Srl | USE OF MONTMORILLONITE IN PATHOLOGIES THAT NEED AN IPOPROTEIC DIET |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007051427A1 (en) * | 2005-11-04 | 2007-05-10 | Zhejiang Hailisheng Pharmaceutical Limited Co. | Modified montmorillonite, method for preparing the same and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169612C (en) * | 2003-01-20 | 2004-10-06 | 浙江大学 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
-
2003
- 2003-04-17 CN CNB2005100827570A patent/CN1314406C/en not_active Expired - Fee Related
- 2003-04-17 CN CN 03121876 patent/CN1267103C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012209411A1 (en) * | 2012-06-04 | 2013-12-05 | Fim Biotech Gmbh | Mineral compound for the reduction of inorganic phosphates, in particular in the context of renal replacement therapy |
| US9585913B2 (en) | 2012-06-04 | 2017-03-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Furschung e.V. | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy |
| WO2014037877A1 (en) * | 2012-09-04 | 2014-03-13 | Irccs Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino | Food product or a seasoning thereof containing bentonite or montmorillonite having activity of metabolic protein load reduction |
| ITMI20130764A1 (en) * | 2013-05-10 | 2014-11-11 | Easy & Good Srl | USE OF MONTMORILLONITE IN PATHOLOGIES THAT NEED AN IPOPROTEIC DIET |
| CN103251648A (en) * | 2013-05-15 | 2013-08-21 | 乔敏 | Iron-based montmorillonite medicine for treating hyperphosphatemia and iron-deficiency anemia and preparation method of iron-based montmorillonite medicine |
| CN103251648B (en) * | 2013-05-15 | 2015-08-05 | 乔敏 | Iron-based montmorillonite medicine for the treatment of hyperphosphatemia and iron deficiency anemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1537541A (en) | 2004-10-20 |
| CN1267103C (en) | 2006-08-02 |
| CN1314406C (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2259981T3 (en) | LAXANT COMPOSITION CONTAINING SIMETICONE. | |
| AU2001244611B2 (en) | Preparations for preventing bile acid diarrhea | |
| CN102579350B (en) | Pidotimod liposome solid preparation | |
| CN1314406C (en) | Application of montmorillonite in pharmacy | |
| CN103393693B (en) | Pharmaceutical composition of ondansetron hydrochloride and dexamethasone | |
| CN1279582A (en) | Serotonin containing formulation or oral administration and method of use | |
| CN1843505A (en) | Compound Doxycycline lysozyme enteral capsule | |
| CN1250227C (en) | Aminoglucose hydrochloride medicinal composition | |
| CN101574339A (en) | Application of beta-anhydroicaritin in preparation of medicine capable of preventing and treating cardiovascular and cerebrovascular diseases | |
| Ryde | Low-molecular-weight azo compounds | |
| CN106361718A (en) | Colon-specific bioadhesive tablet containing monosialotetrahexosyl ganglioside sodium | |
| CN1939494A (en) | Purge capsules for old person and production thereof | |
| CN1457780A (en) | Total alkaloid composition from plant and its pharmaceutical preparation | |
| CN102440959B (en) | Pidotimod liposome solid preparation | |
| CN1839882A (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| WO2022211481A1 (en) | Oral nanoparticles for bioactive compound, and method of preparing same | |
| CN103393701B (en) | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN1279927C (en) | Traditional Chinese medicinal compocition for treating pancreatitis, cholecystitis, appendicitis and acute and chronic gastro enteritis | |
| Chuiko et al. | Medical aspects of application of highly disperse amorphous silica | |
| CN117180408A (en) | CAT-Mg 2+ Nano medicine @ Hep, preparation method and application thereof | |
| CN103393694B (en) | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone acetate | |
| CN102526100B (en) | Pharmaceutical composition containing lappaconitine and iodine | |
| CN102716129B (en) | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Liangzhen Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070509 Termination date: 20100417 |